EULAR Annual Congress
EULAR Annual Congress
June 11, 2016
3 min watch

VIDEO: Khanna discusses safety, efficacy of tocilizumab for systemic sclerosis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

LONDON — At the EULAR Annual Congress, Dinesh Khanna, MD, MSc, spoke about the results of an open-label period of the faSScinate trial. The safety and efficacy of tocilizumab was assessed in patients with systemic sclerosis for 48 weeks of an open-label period.

He said that although the open-label data need to be interpreted with caution, the results indicate the efficacy and safety of the placebo-treated patients who switched to open-label tocilizumab (Actemra, Genentech) were similar to results observed in patients randomized to tocilizumab in the double-blind period. Additionally, results during 96 weeks of treatment with tocilizumab suggested there was a maintenance of the clinical response for the modified Rodnan skin score for patients.